Aptinyx concludes enrolment in Phase IIb fibromyalgia therapy trial
The change in average daily pain scores from baseline to week 12 is the primary endpoint of the trial.

The change in average daily pain scores from baseline to week 12 is the primary endpoint of the trial.
Subject-reported pain at day 14 due to acute back spasm is the primary goal of the trial.
The US FDA's clinical hold on Zolgensma did not just delay Novartis in developing the drug, but allowed its competitors…
ByThe Phase III trial met the primary endpoint with efgartigimod showing improvement in the quality of life of patients.
Recent trial results position Janssen's Tremfya well in the psoriatic arthritis market, but the drug still faces strong competition.
BySarepta Therapeutics presented interim findings from its Phase II clinical trial (Study 102) in Duchenne muscular dystrophy (DMD) for its…
ByTwo-year data from part two of FIREFISH, a Phase II/III global study by Roche evaluating Evrysdi (risdiplam) in infants aged…
ByAmerican Rheumatology Network (ARN) has launched ARN Clinical Research, a patient centric and real-world technology unit for transforming rheumatology trials…
Thank you for subscribing to Clinical Trials Arena